{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:38Z","timestamp":1792172498648,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["XZSR-2023-01"],"award-info":[{"award-number":["XZSR-2023-01"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.apjon.2025.100661","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:55:55Z","timestamp":1738871755000},"page":"100661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Risk factors associated with immune-related severe adverse events in patients with cancer: A scoping review"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0654-4864","authenticated-orcid":false,"given":"Zhenzhen","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-664X","authenticated-orcid":false,"given":"Liyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6477","key":"10.1016\/j.apjon.2025.100661_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science (New York, NY)"},{"issue":"7","key":"10.1016\/j.apjon.2025.100661_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.apjon.2025.100661_bib3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.apjon.2025.100661_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00262-021-03115-y","article-title":"The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol Immunother : CII."},{"issue":"2","key":"10.1016\/j.apjon.2025.100661_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.hemonc.2021.09.005","article-title":"Immune checkpoint inhibitor-induced pneumonitis: incidence, clinical characteristics, and outcomes","volume":"16","author":"Banavasi","year":"2023","journal-title":"Hematology\/oncology Stem Cell Therapy"},{"issue":"16","key":"10.1016\/j.apjon.2025.100661_bib6","first-page":"1169","article-title":"Research progress of myocarditis caused by immune checkpoint inhibitors (ICIs)","volume":"29","author":"Shi","year":"2022","journal-title":"Chin J Cancer Prev Treat"},{"issue":"5","key":"10.1016\/j.apjon.2025.100661_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.resinv.2020.05.008","article-title":"Clinical burden of immune checkpoint inhibitor-induced pneumonitis","volume":"58","author":"Sakamoto","year":"2020","journal-title":"Respiratory Investigation"},{"key":"10.1016\/j.apjon.2025.100661_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108353","article-title":"Adverse events of immunotherapy in non-small cell lung cancer: a systematic review and network meta-analysis","volume":"102","author":"Zhou","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.apjon.2025.100661_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"36","key":"10.1016\/j.apjon.2025.100661_bib10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol Off J Amer Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.apjon.2025.100661_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.apjon.2025.100661_bib12","first-page":"m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ (Clinical research ed)"},{"issue":"15_suppl l","key":"10.1016\/j.apjon.2025.100661_bib13","article-title":"Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data","volume":"38","author":"Jain","year":"2020"},{"issue":"12","key":"10.1016\/j.apjon.2025.100661_bib14","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 Years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-023-01365-3","article-title":"Mechanisms and biomarkers of immune-related adverse events in gastric cancer","volume":"28","author":"Ding","year":"2023","journal-title":"Eur J Med Res"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/imr.13248","article-title":"CD4 T cells and toxicity from immune checkpoint blockade","volume":"318","author":"Earland","year":"2023","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.apjon.2025.100661_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjon.2025.100661_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/CMAR.S293200","article-title":"Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"18","key":"10.1016\/j.apjon.2025.100661_bib20","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","article-title":"Baseline serum Autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade","volume":"28","author":"Johannet","year":"2022","journal-title":"Clin Cancer Res Off J Amer Assoc Cancer Res"},{"key":"10.1016\/j.apjon.2025.100661_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunotherapy Cancer"},{"issue":"4","key":"10.1016\/j.apjon.2025.100661_bib22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.20892\/j.issn.2095-3941.2021.0052","article-title":"Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events","volume":"18","author":"Bai","year":"2021","journal-title":"Cancer biology & medicine"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib23","article-title":"Landscape of immune checkpoint inhibitor-related adverse events in Chinese population","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.apjon.2025.100661_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012641","article-title":"Association between changes in the patterns of antinuclear autoantibodies during immune checkpoint inhibition therapy and the development of severe immune related adverse events","volume":"23","author":"Alserawan","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CJI.0000000000000347","article-title":"Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors","volume":"44","author":"Cho","year":"2021","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.apjon.2025.100661_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000503566","article-title":"Landscape of immune-related pneumonitis in cancer patients with asthma being treated with immune checkpoint blockade","volume":"98","author":"Galant-Swafford","year":"2020","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.apjon.2025.100661_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100107","article-title":"High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors","volume":"6","author":"G\u00fclave","year":"2021","journal-title":"ESMO open"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1722023","article-title":"Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment","volume":"9","author":"Kim","year":"2020","journal-title":"OncoImmunology"},{"issue":"19","key":"10.1016\/j.apjon.2025.100661_bib30","article-title":"Severe late-onset grade III-IV adverse events under immunotherapy: a retrospective study of 79 cases","volume":"13","author":"L'Orphelin","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaoncol.2022.5409","article-title":"Association of body mass index with the safety profile of nivolumab with or without ipilimumab","volume":"9","author":"McQuade","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.apjon.2025.100661_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jjco\/hyac024","article-title":"The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study","volume":"52","author":"Ohe","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study","volume":"10","author":"Okada","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.apjon.2025.100661_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res Off J Amer Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12931-023-02370-0","article-title":"New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"24","author":"Lin","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.apjon.2025.100661_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lungcan.2019.02.011","article-title":"The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment","volume":"130","author":"Sakata","year":"2019","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"5","key":"10.1016\/j.apjon.2025.100661_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.apjon.2025.100661_bib38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.31557\/APJCP.2022.23.2.695","article-title":"Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer","volume":"23","author":"Takada","year":"2022","journal-title":"Asian Pac J Cancer Prev APJCP Asian Pac J Cancer Prev APJCP"},{"issue":"4","key":"10.1016\/j.apjon.2025.100661_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/CJI.0000000000000415","article-title":"Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving PD-1 inhibitors","volume":"45","author":"Zhao","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.apjon.2025.100661_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914928","article-title":"Intrinsic differences in immune checkpoint inhibitor-induced myocarditis: a retrospective analysis of real world data","volume":"13","author":"Lei","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apjon.2025.100661_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"Cortellini","year":"2020","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"issue":"8","key":"10.1016\/j.apjon.2025.100661_bib42","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.apjon.2025.100661_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.apjon.2025.100661_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apjon.2025.100661_bib45","article-title":"Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.apjon.2025.100661_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113480","article-title":"Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: a VigiBase study","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.apjon.2025.100661_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195945","article-title":"Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab","volume":"13","author":"Dumenil","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.apjon.2025.100661_bib48","article-title":"Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.apjon.2025.100661_bib49","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1093\/cid\/ciaa802","article-title":"Impact of checkpoint inhibitor immunotherapy, primarily pembrolizumab, on infection risk in patients with advanced lung cancer: a comparative retrospective cohort study","volume":"73","author":"Malek","year":"2021","journal-title":"Clin Infect Dis Off Publ Infectious Diseases Soc America"},{"issue":"3","key":"10.1016\/j.apjon.2025.100661_bib50","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/ehf2.14340","article-title":"Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity","volume":"10","author":"Liang","year":"2023","journal-title":"ESC heart failure"},{"key":"10.1016\/j.apjon.2025.100661_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125876","article-title":"Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1\/PD-L1 inhibitors in cancer patients","volume":"14","author":"Geng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apjon.2025.100661_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/CMAR.S403569","article-title":"Outcomes of antineoplastic immunotherapy at a large healthcare organization: impact of provider, race and socioeconomic status","volume":"15","author":"Mirsky","year":"2023","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.apjon.2025.100661_bib53","article-title":"Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.apjon.2025.100661_bib54","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1002\/cam4.5816","article-title":"Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"12","author":"Haraguchi","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"issue":"6","key":"10.1016\/j.apjon.2025.100661_bib56","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s10637-022-01310-x","article-title":"Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer","volume":"40","author":"Sumi","year":"2022","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.apjon.2025.100661_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neuro-oncology"},{"issue":"8","key":"10.1016\/j.apjon.2025.100661_bib59","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","article-title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","volume":"119","author":"Fumet","year":"2018","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.apjon.2025.100661_bib60","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jtho.2023.11.017","article-title":"The interplay between the immune system, tumor suppressor genes, and immune senescence in mesothelioma development and response to immunotherapy","volume":"19","author":"Nel","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"7739","key":"10.1016\/j.apjon.2025.100661_bib61","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-018-0812-9","article-title":"Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin","volume":"565","author":"Park","year":"2019","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.apjon.2025.100661_bib62","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and cancer immunotherapy","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin Cancer Res Off J Amer Association for Cancer Research"},{"issue":"14","key":"10.1016\/j.apjon.2025.100661_bib63","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-22-3116","article-title":"Type 2 diabetes Mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer","volume":"29","author":"Cortellini","year":"2023","journal-title":"Clin Cancer Res Off J Amer Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.apjon.2025.100661_bib64","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.apjon.2025.100661_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041382","article-title":"Autoantibody biomarkers in rheumatic diseases","volume":"21","author":"Kang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.apjon.2025.100661_bib66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41467-019-14273-0","article-title":"Comprehensive T cell repertoire characterization of non-small cell lung cancer","volume":"11","author":"Reuben","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.apjon.2025.100661_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunotherapy Cancer"},{"issue":"2","key":"10.1016\/j.apjon.2025.100661_bib68","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jgh.16038","article-title":"Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury","volume":"38","author":"Yamamoto","year":"2023","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562525000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562525000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T21:47:11Z","timestamp":1766440031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2347562525000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"alternative-id":["S2347562525000095"],"URL":"https:\/\/doi.org\/10.1016\/j.apjon.2025.100661","relation":{},"ISSN":["2347-5625"],"issn-type":[{"value":"2347-5625","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with immune-related severe adverse events in patients with cancer: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjon.2025.100661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society.","name":"copyright","label":"Copyright"}],"article-number":"100661"}}